Initial Experience With Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NETS) at a Tertiary Care United States Center

被引：0
|
作者：
Heckert, Jason [1 ]
Botterbusch, Samuel [2 ]
Kipnis, Sarit [1 ]
Bennet, Bonita [3 ]
Creamer, Caroline [3 ]
Alderson, Alice [3 ]
Eads, Jennifer [3 ]
Soulen, Michael [3 ]
Pryma, Daniel [3 ]
Mankoff, David [3 ]
Metz, David [3 ]
Katona, Bryson [3 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Perelman Sch Med, Philadelphia, PA USA
来源：
PANCREAS | 2020年 / 49卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：470 / 471
页数：2
相关论文
共 50 条
  • [11] Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
    Baum, Richard P.
    Wang, Peipei
    Jakobsson, Vivianne
    Zhao, Tianzhi
    Schuchardt, Christiane
    Khong, Pek-Lan
    Zhang, Jingjing
    THERANOSTICS, 2024, 14 (01): : 133 - 142
  • [12] Systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
    Teran Brage, E.
    Campana-Diaz, E.
    Navarro Martin, M.
    Garcia-Talavera, P.
    Lopez Gutierrez, A.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Roldan Ruiz, J.
    Posado Dominguez, L.
    Pablo Martin, E.
    Lozano Mejorada, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [13] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [14] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S469
  • [15] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
    Papamichail, Dimitris G.
    Exadaktylou, Paraskevi E.
    Chatzipavlidou, Vasiliki D.
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (01): : 75 - 83
  • [16] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
    Otte, Andreas
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (02): : 182 - 182
  • [17] Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Bertani, E.
    Chiappa, A.
    Fazio, N.
    Grana, C.
    Bodei, L.
    Falconi, M.
    Ravizza, D.
    Spada, F.
    Andreoni, B.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 285 - 285
  • [18] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [19] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [20] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
12345